Immunai

Immunai is a biotechnology and computational immunology company founded in 2018, co-founded by Luis Voloch and Noam Solomon. The company is headquartered in New York, with a significant R&D presence in Tel Aviv. It is privately held.

Immunai builds a large-scale proprietary immunological database combined with machine learning models to map the human immune system at single-cell resolution. The core thesis is that a detailed, structured map of immune cell states and transitions enables better design and optimization of immunotherapies, particularly cell therapies and cancer treatments.

Immunai's primary product is a platform that integrates single-cell multi-omic data — capturing gene expression, protein levels, and other molecular signals simultaneously from individual immune cells — with machine learning to generate predictive models of immune response. The intended buyers are biopharmaceutical companies developing cell therapies, CAR-T programs, and other immuno-oncology treatments, with the platform aimed at R&D and translational science teams within those organizations. The scientific moat is the proprietary immunological atlas built from accumulated single-cell datasets, which grows in predictive value as more data is ingested.

Immunai maintains an R&D center in Tel Aviv. Co-founder Noam Solomon is Israeli, and the company has drawn from Israeli computational biology and machine learning talent. The Tel Aviv office focuses on data science, machine learning, and computational biology roles.